Get the Stockscreener App
1.065
1.42%
0.01
Humacyte Inc stock is traded at $1.065, with a volume of 5.05M.
It is up +1.42% in the last 24 hours and up +15.04% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.055
Open:
$1.075
24h Volume:
5.05M
Relative Volume:
0.65
Market Cap:
$289.86M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.8531
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
-22.46%
1M Performance:
+15.04%
6M Performance:
-9.32%
1Y Performance:
-54.85%
1-Day Range:
$1.06
$1.11
1-Week Range:
$1.00
$1.50
52-Week Range:
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.075 | 284.47M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
450.24 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.82 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
881.07 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.82 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Canada
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Bioengineered blood vessel helps women on dialysis avoid catheters longer - Stock Titan
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Director at Humacyte (NASDAQ: HUMA) receives 80,000 stock options grant - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 strike price - Stock Titan
Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse - Stock Titan
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte (HUMA) director Keith Anthony Jones awarded 80,000 stock options at $1.08 - Stock Titan
Humacyte (HUMA) director receives grant of 80,000 stock options at $1.08 strike - Stock Titan
Director at Humacyte (NASDAQ: HUMA) granted 80,000 stock options - Stock Titan
Director at Humacyte (HUMA) receives grant of 80,000 stock options - Stock Titan
Humacyte (HUMA) director Emery N. Brown receives 80,000 stock options award - Stock Titan
H.C. Wainwright raises Humacyte stock price target on trial data - Investing.com UK
Humacyte prices $50M public offering of common stock at $1.05/share - MSN
H.C. Wainwright raises Humacyte stock price target on trial data By Investing.com - Investing.com Australia
Humacyte Announces Proposed Public Offering to Fund Commercialization of Symvess and Pipeline Development - Minichart
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
HUMA Maintained by HC Wainwright & Co. -- Price Target Raised to $4.00 - GuruFocus
Humacyte Announces Underwritten Public Equity Offering to Fund Growth - TipRanks
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M - TradingView
Humacyte (HUMA) prices 47.6M-share stock sale at $1.05 to fund Symvess - Stock Titan
Humacyte (NASDAQ: HUMA) priced 47.6M shares at $1.05; Phase 3 met endpoint - Stock Titan
Why Is Humacyte Stock Falling Thursday? - Benzinga
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $4 - Moomoo
Humacyte stock falls despite positive Phase 3 data - scanx.trade
Biggest stock movers: ORCL, HUMA, and more - Seeking Alpha
Humacyte (HUMA) Phase 3 trial meets dialysis access endpoint - grafa.com
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock - Quiver Quantitative
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing - Stock Titan
Humacyte prices $50 million public offering at $1.05 per share - Investing.com
Humacyte prices $50 million public offering at $1.05 per share By Investing.com - Investing.com India
Humacyte stock falls 6% on public offering announcement - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Benzinga
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses - Stocktwits
Humacyte reports positive Phase 3 trial results for dialysis access By Investing.com - Investing.com South Africa
Humacyte Announces Positive Phase 3 Dialysis Access Results - TipRanks
Stocks to Watch : Oracle, Oxford Industries, Humacyte, PureCycle Technologies - marketscreener.com
Humacyte launches public offering of common stock By Investing.com - Investing.com South Africa
Humacyte reports positive Phase 3 trial results for dialysis access - Investing.com
Humacyte launches public offering of common stock - Investing.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):